Exact Sciences Corp

Exact Sciences Corp is a leading molecular diagnostics company specializing in cancer screening and diagnostic tests. Its flagship product, Cologuard, is a non-invasive stool-based DNA test designed to detect colorectal cancer and pre-cancer through DNA and hemoglobin biomarkers. The company also offers the Oncotype DX suite, including Breast Recurrence Score, Breast DCIS Score, and Colon Recurrence Score tests, which are genomic assays that assess recurrence risk and chemotherapy benefits for breast and colon cancer patients. Additional products include OncoExTra for comprehensive tumor profiling in advanced cancers and Oncodetect for molecular residual disease monitoring. Exact Sciences Corp serves the precision oncology market with tissue-based and liquid-based tests, alongside initiatives in multi-cancer early detection like Cancerguard. Operating in the United States and internationally, it supports healthcare providers and patients in prevention, early detection, and personalized treatment guidance. Founded in 1995 and headquartered in Madison, Wisconsin, Exact Sciences Corp plays a key role in advancing non-invasive cancer diagnostics.